Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Transition Therapeutics says Alzheimer’s drug effective in sub-group

Written by: | no-reply@reuters.com | Dated: Thursday, October 15th, 2015

Drug developer Transition Therapeutics Inc said its experimental drug reduced severe agitation and aggression in Alzheimer’s patients, citing data from a large study.

The company said on Thursday that it would use the data to discuss a potential late-stage trial of the drug, ELND005, with the U.S. Food and Drug Administration.

The company said in June that the large study did not reduce moderate-to-severe agitation and aggression, pushing its U.S.-listed shares down as much as 20 percent that day.

The latest analysis identified a sub-group within those patients, who reacted positively to the drug.

ELND005 is the lead experimental drug that Transition Therapeutics is testing. The Canadian developer has also completed a mid-stage study of the drug in Down Syndrome patients.

Transition Therapeutics’ U.S.-listed shares closed at $1.93 on Wednesday. The stock has fallen about 20 percent since the company reported initial results in June.

 

(This story has been corrected to fix typo in first paragraph.)

 

(Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian and Anil D’Silva)

Source: Reuters Health

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom